Skip to main content
. 2021 Aug 16;131(16):e147552. doi: 10.1172/JCI147552

Figure 10. The levels of CHI3L1, LGALS3, and LGALS3BP mRNA expression predict anti–PD-1 response in GBM patients.

Figure 10

(A) Histogram analysis of the distribution of anti–PD-1 treatment responders and nonresponders in GBM patients following anti–PD-1 treatment from a previous data set (41). The n represents the number of patients characterized with indicated gene expression. (B) Schematic drawing indicates that glioma cell–intrinsic CHI3L1 binding with Gal3 forms a protein-binding complex modulating the TAM-mediated immune microenvironment for tumor progression, which is negatively regulated by Gal3BP or GMP.